National Genetics Institute
National Genetics Institute is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, vs Investigator's Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Enrollment into the MORAb-202 33 mg/m² arm was closed because of emerging safety concerns regarding pneumonitis/interstitial lung disease at that dose level.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
Sponsor Not reported
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The trial was withdrawn with 0 patients enrolled.
These findings describe the trial, not the service provider’s performance or responsibility.
A Randomized, Double-Blind, Phase II Study of BMS-986315 and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Only 1 participant enrolled worldwide, in the United States; no participants enrolled in the EEA.
- Part 2 enrolled no participants because the study was terminated.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for National Genetics Institute?
The 2026-10-09 snapshot links National Genetics Institute to 4 distinct CTIS trials. Recorded services include Laboratory services, BMA: FISH analysisBMB: processing and IHC testing, IHC Biomarker expression analysis (PD-L1), other APH, IHC Biomarker expression analysis (PD-L1), other APH, Routine clinical pathology testing, Clinical chemistry, Clinical haematology, Clinical microbiology, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for National Genetics Institute?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology, Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to National Genetics Institute conducted?
The linked trials record locations in 16 countries, including Spain, Italy, Belgium, France, Romania. These are trial locations, not confirmed office locations or countries where National Genetics Institute delivered services.
What can this page tell me about National Genetics Institute's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under National Genetics Institute. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- National Genetics Institute